



Evidence Based Use of T3+T4 Combinations: London, UK & Chicago USA
Sunday, November 3, 2019
A Joint American Thyroid Association® (ATA®)/ British Thyroid Association (BTA)/
European Thyroid Association (ETA) Symposium

AGENDA

USA-CST	UK-BST		
06:30-07:00	12:30-13:00	Registration: Breakfast/Lunch (depending on attendance location – US or UK)	
07:00-07:10 (10 mins)	13:00-13:10 (10 mins)	Introduction and Symposium Format	Colin Dayan (UK) Jacqueline Jonklaas (US)
Session 1: The Scientific Background			Chair: Anita Boelen (UK)
07:10-07:40 (30 mins)	13:10-13:40 (30 mins)	Keynote: Local Control of Thyroid Hormone Action, DIO2 Polymorphisms and the Effects of L-Thyroxine	Antonio Bianco (US)
07:40-08:00 (20 mins)	13:40-14:00 (20 mins)	Non Classical Actions of Thyroid Hormone	Lars Moeller (UK)
08:00-08:20 (20 mins)	14:00-14:20 (20 mins)	Thyroid Hormone Transporters and CNS Levels of Thyroid Hormone	Heike Heuer (UK)
08:20-08:30 (10 mins)	14:20-14:30 (10 mins)	Discussion	
Session 2: Dosing Regimes in Clinical Trials of T3/T4			Chair: Birte Nygaard (UK)
08:30- 08:55 (25 mins)	14:30-14:55 (25 mins)	T3/T4 Dose Equivalence – Clinical and Trial Data	Francesco Celi (US)
08:55-09:20 (25 mins)	14:55-15:20 (25 mins)	Target T3 and TSH levels and Slow Release T3	Richard Ross (UK)
09:20-09:30 (10 mins)	15:20-15:30 (10 mins)	Discussion	
09:30-09:45 (15 mins)	15:30-15:45 (15 mins)	Break	
Sessions 3: Trial Endpoints – Measuring Benefit			Chair: Anna Sawka (US)
09:45-10:10 (25 mins)	15:45-16:10 (25 mins)	Psychological and Quality of Life Measures	Torquil Watt (UK)
10:10-10:35 (25 mins)	16:10-16:35 (25 mins)	Biological Outcomes, Biomarkers and Safety Measures	Anne Cappola (US)
10:35-10:45 (10 mins)	16:35-16:45 (10 mins)	Discussion, Wrap Up, and Transition to Practical Sessions	
Session 4: Practical Management of Patients on T3 and NDT			Chair: Colin Dayan (UK) Chair: Jacqueline Jonklaas (US)
N/A (UK only)	16:45-17:30	Local expert lead small group workshops on: patient selection; monitoring; stopping therapy; evaluation of response; long term follow-up	Colin Dayan (UK) Eric Fliers (UK)
10:45-11:15	N/A (US only)	Discussion of Patient Experiences on Therapy for Hypothyroidism	Elizabeth McAninch (US) Along with 2 patients

Visit www.thyroid.org, www.british-thyroid-association.org or www.eurothyroid.com for more information.
 For European registration contact: endocrinology&diabetes@cardiff.ac.uk



Evidence Based Use of T3+T4 Combinations: London, UK & Chicago USA
Sunday, November 3, 2019
A Joint American Thyroid Association® (ATA®)/ British Thyroid Association (BTA)/
European Thyroid Association (ETA) Symposium

Endocrinologists are frequently asked to consult on patients taking L-thyroxine (T4) but appear dissatisfied with their therapy. However, the use of combination therapy with liothyronine (T3) remains highly controversial with conflicting results from clinical trials. Recent scientific studies have provided new insight into the complex relationship between serum and tissue thyroid hormone levels justifying a review of the evidence base for the use of T4+T3 combinations and the design of future clinical trials in this area.

This innovative symposium will occur simultaneously in Chicago, US and London, UK, representing a collaborative effort between the ATA, BTA and ETA, to bring together leading experts in this area from North America and Europe. It will be a live meeting in both locations, with the UK audience accessing a webcast to view the US presentations and the US audience accessing a webcast to view the UK presentations with the opportunity for both audiences to ask questions to all speakers. The symposium will conclude with fully interactive workshops on the use of combination therapy in the UK, and a patient discussion forum in the US. Co-chaired by U.S. based Jaqueline Jonklaas, MD and U.K. based Colin M. Dayan, MA, FRCP, PhD, the anticipated goal is to use the symposium content and discussion as material to produce a consensus statement about the design of future combination therapy trials and to assist endocrinologists in advising their patients on the current evidence base behind combination therapy.

WHEN: Sunday, November 3, 2019, see agenda on reverse side for times

WHERE AND HOW TO REGISTER

For U.S. Participants: Live program included as part of the overall 89th Annual Meeting of the ATA®, October 30 – November 3, 2019 at the Sheraton Grand Chicago, Chicago, IL. Registration for the 89th Annual Meeting of the ATA will open in mid-April 2019 at www.thyroid.org.

For U.K. Participants: U.K. live program will take place at the Amba Hotel Marble Arch, Bryanston, Street, London, W1H 7EH. Additional details and link to register will be available on the BTA and ETA website.

IMPORTANT NOTE: No virtual stream will be available to attendees not participating in either the US or UK live meetings.

PARTICIPATING FACULTY

Colin M. Dayan, MA, FRCP, PhD, Co-Chair Cardiff University, Cardiff, UK	Jacqueline Jonklaas, MD, Co-Chair Georgetown University Washington, DC, USA	Antonio C. Bianco, MD, PhD University of Chicago Chicago, IL, USA
Anita Boelen, PhD University of Amsterdam The Netherlands	Anne R. Cappola, MD, ScM University of Pennsylvania School of Medicine, Philadelphia, PA, USA	Francesco S. Celi, MD Virginia Commonwealth University, Richmond, VA, USA
Eric Fliers, MD, PhD University of Amsterdam The Netherlands	Heike Heuer, PhD University Hospital Essen Essen, Germany	Elizabeth A. McAninch, MD Rush University Medical Center, Chicago, IL, USA
Lars C. Moeller, MD PhD University of Duisburg Essen, Germany	Birte Nygaard, PhD Herlev University Hospital Copenhagen, Denmark	Richard J. Ross, MD, FRCP University of Sheffield Sheffield, UK
Anna M. Sawka, MD, PhD University of Toronto Toronto, Ontario, Canada	Torquil Watt, MD, PhD, DMSc Herlev University Hospital Copenhagen, Denmark	